Session » Rheumatoid Arthritis – Etiology and Pathogenesis Poster III

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2039

A Survey of Blood and Synovial Tissue Myeloid Cells in RA Patients By Transcriptional Profiling

9:00AM-11:00AM: Abstract Number: 2036

Adenosine Receptors Expression As Predictor of Response to Methotrexate Therapy in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2057

Alterations of the Splicing Machinery in Leukocyte Subsets of Rheumatoid Arthritis Patients Modulate Their Inflammatory, Autoimmune and Atherothrombotic Profiles

9:00AM-11:00AM: Abstract Number: 2050

B and T Cell Phenotypes of First Degree Relatives of RA Patients in an Indigenous North American Cohort

9:00AM-11:00AM: Abstract Number: 2056

Citrullination Is Not a Determinant in the Lack of Tolerance to Peptidylarginine Deiminase 2 and 4 in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2037

CTLA4 Signaling Down-Regulates Fcγ Receptor I Expression on Circulating Monocytes: A Potential Mechanism of Action of Abatacept for RA

9:00AM-11:00AM: Abstract Number: 2035

Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2049

Expression and Function of a Novel Citrullinated Form of Interleukin 6 in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2040

Galectin-3 Is a Regulator of 4-1BB/CD137 Activity and Associates with Outcome in Rheumatoid Arthritis.

9:00AM-11:00AM: Abstract Number: 2053

Global Mirna Expression and Transcriptomic Profiling of Monocytes from RA Patients

9:00AM-11:00AM: Abstract Number: 2052

Immune Therapy of Rheumatoid Arthritis Patients with a Microbiome-Derived, Self/Non-Self Peptide Induces Clinically Relevant Immune Tolerance Pivoting on Immune Checkpoint-Expressing, Therapy-Induced Tregs

9:00AM-11:00AM: Abstract Number: 2042

Immunophenotypic Analysis of Tissue-Resident Memory T Cells in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2044

Impaired microRNA Processing in Neutrophils from Rheumatoid Arthritis Patients Confers Their Pathogenic Profile. Modulation By Biological Therapies

9:00AM-11:00AM: Abstract Number: 2054

In Rheumatoid Arthritis, Changes in Autoantibody Levels Do Not Associate with Treatment Response, but Are a Reflection of Treatment Intensity

9:00AM-11:00AM: Abstract Number: 2048

In Vitro Proof-of-Concept of Pathobiology-Guided Therapy in Immune Mediated Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2055

Laser Capture Microdissection to Interrogate B Cells in RA Synovial Tissue

9:00AM-11:00AM: Abstract Number: 2043

Monocytes and Macrophages of Patients with Rheumatoid Arthritis Respond to Pathologically Increased Ionized Calcium with Proinflammatory Cytokine Production

9:00AM-11:00AM: Abstract Number: 2051

Rheumatoid Factor Peptide Expression By Quantitative Proteomics Delineates Responsive and Resistant Clones after Treatment of Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2046

Serum Immunoglobulin G Targets Citrulline-Containing Immunoglobulin G Peptides in Rheumatoid Arthritis Patients Who Test Positive for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies

9:00AM-11:00AM: Abstract Number: 2041

Serum Level of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1): A New Biomarker of Disease Activity in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2045

Specific Anti-Citrullinated Protein Antibodies Profiles Are Associated with Rheumatoid Arthritis Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2038

Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2047

Synovial Fluid Cytokines /Chemokines and Proteins from the Knees of Symptomatic RA and OA Patients Which Correlate with the Magnitude of the Inflammatory Response As Measured By Synovial Fluid WBC Levels

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].